Industry symposia

IDF 2022 will run over 3 days and include 120 hours of scientific sessions. It will feature more than 250 international speakers including some of the top experts in diabetes today. 

Industry symposia are an integral part of the IDF World Diabetes Congress 2022 programme, offering high quality programmes and high-level speakers.

Companies operating in the field of diabetes value IDF Congresses as relevant and impactful opportunities to present the latest research and share innovative products with an international audience of health professionals. 

An overview of the satellite symposia programme is available below.

All times WET (UTC+0).

Tuesday - December 6
12.30-13.30
Auditorium VIII

Nonsteroidal MRAs in CKD and T2D: Current knowledge and practical insights
Programme
Chair: Per-Henrik GroopWelcome and introduction

Time to act in T2D: CKD as a driver of CV and renal outcomes
Speaker: Per-Henrik Groop

The cardiorenal benefits of nonsteroidal MRAs: Insights from across the CKD in T2D patient spectrum
Speaker: Antonio Ceriello

Programme
Finerenone in clinical practice: Approaches for optimising the patient experience
Speaker: Rita Birne

Q&A and CloseSpeaker: Per-Henrik Groop - All Faculty
Previous
Next

Tuesday - December 6
12:30 - 13:30
Auditorium III/IV

Determining a personal approach: Finding balance in Type 2 diabetes management
Programme
Chair: Emma Wilmot, United Kingdom

Welcome and Introductions
Emma Wilmot, United Kingdom

Perspective is reality: Equating health determinants and outcomes
Speaker: Jean Claude Mbanya, Cameroon

Balancing outcomes for people with T2D receiving insulin-based therapies
Speaker: Mohamed Hassanein, Egypt

Attaining a personal approach: The role of digital support in care
Speaker: Partha Kar, United Kingdom

Q&A and closing summary
All faculty
Previous
Next

Tuesday - December 6
17.30-19.30
Auditorium VIII

Demystifying the Evolving Science of and Potential Role of Incretins in T2D
Programme
Chair: Professor Bernhard Ludvik, Austria

Welcome and Introductions
Professor Bernhard Ludvik, Austria

Addressing Unmet Needs in T2D: Comorbidities, Treatment Intensification, Shared Decision Making for Weight Management
Speaker: Professor Bernhard Ludvik, Austria

Demystifying the Evolving Science Behind the Incretin Effect and the Roles of GLP-1 and GIP Benefits of Agonism of Multiple Receptors that Affect Energy Homeostasis Mechanism of Action of Unimolecular Dual Agonists
Speaker: Dr. Thomas Forst, Germany

Programme
Clinical Implications of Tirzepatide Efficacy and Safety Data Identifying Ideal Candidates for Tirzepatide
Speaker: Professor Stefano Del Prato, Italy

Ask Me Anything: Incretins EditionFinal Q&A with All Faculty

Concluding Comments and Key pointsChair: Professor Bernhard Ludvik, Austria

RSVP here
Previous
Next

Wednesday - December 7
12.30-13.30
Auditorium II

The Global diabetes pandemic calls for new ways to drive access to innovation and personalised care
Programme
Chairs: Viswanathan Mohan (India) and Bruno Almeida (Portugal)

Introduction

How data research, modeling and digital innovation support improved care for people with diabetes in low- and middle-income countries
Speaker: Abdul Basit, Pakistan

Self-monitoring of blood glucose is still a pivotal part in type 2 diabetes management
Speaker: Viswanathan Mohan, India

Integrated Personalised Diabetes Management helps to advance diabetes care in Thailand - a clinical example
Speaker Nitchakarn Laichuthai, Thailand
Previous
Next

Wednesday - December 7
17.30-19.30
Auditorium III/IV

The Fred Hollows Foundation & International Agency for the Prevention of Blindness (IAPB): Eyes, Kidneys and Feet: Joining Forces
Programme
This panel will explore how different diabetes complications are integrated, with a particular focus on the implications for DR integration in primary care in Lower and Middle Income Settings. It will examine the different ways diabetes complications are diagnosed and treated; asking the question, are Kidneys and Feet better integrated than DR? And if so, what are the implications for patients and what can we do to push for better DR integration?

Panel Chair: Professor Serge Resnikoff

Programme
Panellists:

Professor Andrew Boulton, IDF President and Diabetic Foot Specialist, UK

Dr Cova Bascaran, Ophthalmology perspective, UK

Edith Mukantwari, Lived Experience of Diabetes, UK
Previous
Next

Tuesday - December 6
12:30 - 13:30
Auditorium VI/VII

Perhaps Your Next Diabetes Prescription is not a Medication at all
Programme

Chair: Christine Pospisil, United States

Introduction and programme objectives
Speaker: Christine Pospisil, United States

Enhance existing models of care with dexcom cgm
Speaker: Grazia Aleppo, United States

Onboarding and Early Clinical Experience with Dexcom One
Speaker: Dr. Sharona Azriel, Spain

Previous
Next

Tuesday - December 6
12:30 - 13:30
Auditorium II

When practice meets evidence – new data on sulphonylureas from real world evidence
Programme

Chair: Dr. Kamlesh Khunti, United Kingdom

Introduction and programme objectives
Speaker: Dr. Kamlesh Khunti, United Kingdom

ADD2DIA – Real-world clinical effectiveness and patient insight associated with adding SGLT-2i to Gliclazide MR
Speaker: Mussa Almalki, Saudi Arabia

New real-world evidence on the quality of life of Sulphonylureas users in Asia – The JADE Study
Speaker: Juliana Chan, Hong Kong SAR, China

Expert commentary – how real-world evidence is integrated with the t2d environment
Speaker: Aslam Amod, South Africa

Previous
Next

Wednesday - December 7
12:30 - 13:30
Auditorium III/IV

Addressing the Global Amputation Pandemic – Improving Outcomes and Health Inequalities by putting Diabetic Foot Ulcers (DFU) into Remission
Programme
Chair: Andrew Boulton, United Kingdom

Introduction
Chair: Andrew Boulton, United Kingdom

The Growing Global Prevalence of Diabetic Foot Ulcers (DFU)
Speaker: Andrew Boulton, United Kingdom

Diabetic Foot related Amputations and Health Disparities
Speaker: Matthew Garoufalis, USA

Programme
Reducing Hospitalizations and Amputations while Improving Health Inequalities with Topical Wound Oxygen (TWO2) at home Therapy
Speaker: Michael Griffiths, USA

Discussions and Closing
Chair: Andrew Boulton, United Kingdom
Previous
Next

Wednesday - December 7
12.30-13.30
Auditorium VIII

Insights from guidelines and clinical trial: Optimal pathway for treating neuropathic pain in diabetes mellitus (OPTION-DM Study)
Programme
What do the latest guidelines tell us about the management of painful diabetic neuropathy?
Speaker: Gordon Smith, USA

The latest clinical trial evidence on painful diabetic neuropathy: OPTION-DM
Speaker: Solomon Tesfaye, United Kingdom

Question and Answer
Previous
Next

Tuesday - December 6
12.30 -13.30
Auditorium V

Co-Morbidities Affecting our Type 2 Diabetes Patients: A Deeper Look at SGLT2i Effects on Heart Failure, Weight and Other Co-Morbidities from the VERTIS CV Trial
Programme
Co-Chairs: Samuel Dagogo-Jack (USA); Mariana Monteiro (Portugal)

Opening remarks
A Deeper Look at SGLT2i Effects on Weight and Other Co-Morbidities from the VERTIS CV Trial
Speaker: Ildiko Lingvay (USA)

Latest Understanding of Heart Failure from the VERTIS CV Study
Speaker: Francesco Cosentino, Sweden

A Cross-Specialty Faculty Roundtable Discussion: What This Latest Information from VERTIS CV Means For Our Patients
Facilitator: Samuel Dagogo-Jack, USA
Closing remarks
Previous
Next

Tuesday - December 6
17:30 - 18:30
Auditorium III/IV

Delivering value through innovative care delivery for T2 patients
Programme
Chair: Samuel Chevalier, France

Welcome and Introductions

Diabetes from the perspective of integrated care
Speaker: Professor Joao Filipe Raposo, Portugal

Digital Tools combined with diabetes nurse educator support for managing T2 Diabetes in South Africa
Speaker: Dr Cecile Delval, France

Questions and Answers, Closing summary
Samuel Chevalier, France

Previous
Next

Wednesday - December 7
12.30-13.30
Auditorium V

Metformin 100: Diabetes continuum
Programme
Chair: Professor Clifford Bailey, UK

Introduction: One century with metformin
Speaker: Professor Clifford Bailey, United Kingdom

65 years of Metformin in Diabetes
Speaker: Professor Clifford Bailey, United Kingdom

Almost 20 years of prediabetes
Speaker: Associated Professor Aimee Andag-Silva, Philippines

Almost 1 year of Metformin during pregnancy and in periconceptional phase
Speaker: Professor Fidelma Dunne, Ireland

Conclusion: A new century for metformin
Speaker: Prof. Clifford Bailey, United Kingdom
Previous
Next

Wednesday - December 7
17.30-19.30
Auditorium I

Nerve Health in spotlight: Uncovering diabetic peripheral neuropathy
Programme
Chair: Dr S. Azmi, United Kingdom

DPN: The Cinderella complication
Speaker: Prof R. Malik, Qatar

The one-stop-shop screening: how to standardize monitoring of diabetes complications
Speaker: Prof S. Tesfaye, United Kingdom

Panel Discussion

The importance of dental health in diabetes: how to link diabetes, DPN and periodontitis
Speaker: Prof B. Klinge, Sweden
Previous
Next